

Case Report

Challenges in diagnosis and treatment refractory neonatal seizures in immature brain

Ilija G. Palic^{1*}, Olgica P. Rakic²

¹Neonatal Intensive Care Unit, Institute of Neonatology, Belgrade, Serbia

²Department for Admission and Specialized Transport of Neonates, Institute of Neonatology, Belgrade, Serbia

Received: 05 May 2025

Revised: 11 June 2025

Accepted: 21 June 2025

*Correspondence:

Dr. Ilija G. Palic,

E-mail: palicilija152@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Seizures are the most common clinical signs of neurologic dysfunction in neonates. The risk for seizures is inversely related to gestational age and birth weight. Several factors contribute to excessive excitation in the immature brain, such as depolarizing action of γ -aminobutyric acid, change of the subunit composition of the glutamate receptors and incomplete glial clearance of glutamate and potassium. Continuous EEG is the gold standard for diagnosing neonatal seizures. However, video EEG recording has several limitations, especially in preterm neonates. In recent years, amplitude-integrated EEG has been used to detect electrographic seizures. In accordance with the current recommendations, if neonatal seizures do not stop to phenobarbitone, levetiracetam or phenytoin may be used as a second-line anti-seizure medications, as well as midazolam or lidocaine. Midazolam is recommended in the treatment for refractory seizures in neonates requiring mechanical ventilation. In this report, we present a diagnostic and treatment dilemmas of refractory seizures in extremely preterm neonate.

Keywords: Anti-seizure medication, Electroencephalography, Neuromonitoring, Neonatal seizures, Preterm new-born

INTRODUCTION

Seizures are the most common clinical manifestation of neurologic dysfunction in neonates. The incidence to seizures is higher in the developing brain, during neonatal period. The risk for seizures is inversely related to gestational age and birth weight.^{1,2} The more frequent occurrence of seizures in neonates, especially born preterm, is associated with the brain immaturity and the neurophysiological changes in function of receptors for neurotransmitters, such as γ -aminobutyric acid and glutamate.^{3,4}

Structural brain lesions, such as periventricular-intraventricular hemorrhage and focal necrosis in white matter of the brain termed periventricular leukomalacia, are common causes of seizures in neonates born preterm. There are challenges to diagnose seizures in preterm neonates, because they may have many various repetitive

movements which resemble seizures or have only electrographic seizures.⁵ We report a diagnostic and treatment dilemmas of refractory seizures in extremely preterm neonate.

CASE REPORT

A 25 weeks of gestation male neonate was born by vaginal delivery to a 33-years-old primigravida mother, with a birth weight of 700 g and Apgar scores of 3 at first minute and 5 at five minutes after birth. Mother was diagnosed with thrombophilia, hypothyroidism, insulin resistance and chorioamnionitis.

The pregnancy was complicated by cervical incompetence treated with cervical stitch about two months before delivery. Also, the rupture of the fetal membranes occurred 6 days before delivery, so the mother received antibiotic therapy. After initial stabilization in the maternity ward,

function and impact hypoxia to immature brain. Video EEG recording had done after stabilization of respiratory function, when the neonate was on conventional mechanical ventilation. Interictal video EEG did not show epileptic discharges.

In the hospital the three most common used ASMs are phenobarbitone, midazolam and levetiracetam. We started phenobarbitone, as a first choice ASM, although it has been shown to stop seizures in about 50% of cases.^{5,6,12} In accordance with the current recommendations, if neonatal seizures do not stop to phenobarbitone, levetiracetam or phenytoin may be used as a second choice ASM, as well as midazolam or lidocaine.^{13,14} Because of side effects, such as hypotension, respiratory and CNS depression, midazolam is recommended in the treatment for refractory seizures and status epilepticus, especially in neonates requiring mechanical ventilation.^{13,15,16}

Due to its favorable pharmacokinetics and safety profile, the use of levetiracetam in the treatment of neonatal seizures has increased significantly. The metabolism of levetiracetam does not take place in the liver, it has less interactions with other medications, as well as less side effects.^{15,17} Also, its neuroprotective effect is highlighted.^{18,19}

In neonatal seizures unresponsive to second-line ASM and with unknown seizure etiology, it is recommended that neonates receive pyridoxine, a form of vitamin B6, due to possible neonatal onset of pyridoxine-dependent epilepsy.¹³

A special challenge in the treatment of neonatal seizures that should not be forgotten is the immaturity of the liver and kidneys and changes in pharmacokinetics in neonates than older children and adult. There are variations in distribution, metabolism and excretion of ASMs, such as a slowed process of conjugation and other biochemical reactions in drug metabolism, slowed clearance, as well as a prolonged elimination half-life.²⁰⁻²⁴

CONCLUSION

Neonatal seizures are common in preterm neonates, especially in extremely preterm neonates, who are increasingly surviving due to advances in neonatal intensive therapy and care. Seizures in preterm neonates is associated with increased risk for poor neurodevelopmental outcome and epilepsy during childhood, so their early recognition and treatment is necessary. Nevertheless, phenobarbitone is still recommended as a first choice ASM, but it also emphasizes the importance of using midazolam and levetiracetam for the treatment of refractory neonatal seizures.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: Not required

REFERENCES

- Spagnoli C, Pisani F. Acute symptomatic seizures in newborns: a narrative review. *Acta epileptol.* 2024;6:5.
- Pisani F, Spagnoli C, Falsaperla R, Nagarajan L, Ramantani G. Seizures in the neonate: A review of etiologies and outcomes. *Seizure.* 2021;85:48-56.
- Nardou R, Ferrari DC, Ben-Ari Y. Mechanisms and effects of seizures in the immature brain. *Semin Fetal Neonatal Med.* 2013;18(4):175-84.
- Carrasco M, Stafstrom CE. How early can a seizure happen? pathophysiological considerations of extremely premature infant brain development. *Dev Neurosci.* 2018;40(5-6):417-36.
- Rao LM, Marcuccilli CJ. Seizures in the Preterm Neonate. *Neoreviews.* 2017;18(1):52-9.
- Spagnoli C, Falsaperla R, Deolmi M, Corsello G, Pisani F. Symptomatic seizures in preterm newborns: a review on clinical features and prognosis. *Ital J Pediatr.* 2018;44(1):115.
- Vučetić Tadić B, Kravljanić R, Sretenović V, Martić J, Vukomanović V. The features of neonatal seizures as predictors of drug-resistant epilepsy in children. *Epilepsy Behav.* 2020;106:107004.
- Pressler RM, Cilio MR, Mizrahi EM, Moshé SL, Nunes ML, Plouin P, et al. The ILAE classification of seizures and the epilepsies: modification for seizures in the neonate. position paper by the ILAE task force on neonatal seizures. *Epilepsia.* 2021;62(3):615-28.
- Ziobro J, Pilon B, Wusthoff CJ, Benedetti GM, Massey SL, Yozawitz E, et al. Neonatal seizures: new evidence, classification and guidelines. *Epilepsy Curr.* 2024:152.
- Jacobs J, Spelbrink EM. Seizures in preterm infants. *J Clin Neurophysiol.* 2016;33(5):382-93.
- Kim EH, Shin J, Lee BK. Neonatal seizures: diagnostic updates based on new definition and classification. *Clin Exp Pediatr.* 2022;65(8):387-97.
- Painter MJ, Scher MS, Stein AD, Armatti S, Wang Z, Gardiner JC, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. *N Engl J Med.* 1999;341(7):485-9.
- Pressler RM, Abend NS, Auvin S, Boylan G, Brigo F, Cilio MR, et al. Treatment of seizures in the neonate: Guidelines and consensus-based recommendations-special report from the ILAE task force on neonatal seizures. *Epilepsia.* 2023;64(10):2550-70.
- Neubauer D, Soltirovska-Salamon A, Osredkar D, Paro-Panjan D. Management of refractory neonatal seizures. *Res Rep Neonatol.* 2014;4:17-29.
- Abiramalatha T, Thanigainathan S, Ramaswamy VV, Pressler R, Brigo F, Hartmann H. Antiseizure medications for neonates with seizures. *Cochrane Database Syst Rev.* 2022;2022(3):14967.
- Zeller B, Giebe J. Pharmacologic Management of Neonatal Seizures. *Neonatal Netw.* 2015;34(4):239-44.
- Ramantani G, Ikonomidou C, Walter B, Rating D, Dinger J. Levetiracetam: safety and efficacy in

- neonatal seizures. *Eur J Paediatr Neurol.* 2011;15(1):1-7.
18. Komur M, Okuyaz C, Celik Y, Resitoglu B, Polat A, Balci S, et al. Neuroprotective effect of levetiracetam on hypoxic ischemic brain injury in neonatal rats. *Childs Nerv Syst.* 2014;30(6):1001-9.
 19. Talos DM, Chang M, Kosaras B, Fitzgerald E, Murphy A, Folkert RD, et al. Antiepileptic effects of levetiracetam in a rodent neonatal seizure model. *Pediatr Res.* 2013;73(1):24-30.
 20. El-Dib M, Soul JS. The use of phenobarbital and other anti-seizure drugs in newborns. *Semin Fetal Neonatal Med.* 2017;22(5):321-27.
 21. Pacifici GM. Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics. *Curr Pediatr Rev.* 2016;12(1):48-54.
 22. Agrawal A, Banergee A. A review on pharmacokinetics of levetiracetam in neonates. *Curr Drug Metab.* 2017;16;18(8):727-34.
 23. Tulloch JK, Carr RR, Ensom MH. A systematic review of the pharmacokinetics of antiepileptic drugs in neonates with refractory seizures. *J Pediatr Pharmacol Ther.* 2012;17(1):31-44.
 24. Pacifici GM. Clinical pharmacology of midazolam in neonates and children: effect of disease-a review. *Int J Pediatr.* 2014;2014:309342.

Cite this article as: Palic IG, Rakic OP. Challenges in diagnosis and treatment refractory neonatal seizures in immature brain. *Int J Res Med Sci* 2025;13:2993-6.